Biodesix at 45th Annual William Blair Growth Stock Conference: Lung Health Focus

Biodesix (BDSX) presented at the William Blair Growth Stock Conference, highlighting a 21% year-over-year revenue growth in Q1 2024, driven by lung health diagnostics and development services, with gross margins maintained near 80%. The company plans to expand its U.S. sales force to 95 representatives by year-end, targeting primary care physicians, and aims to achieve adjusted EBITDA breakeven in Q4 2025, revising its fiscal year revenue guidance to $80-$85 million. A key strategic goal is the anticipated inclusion in updated ACCP guidelines in 2025, supported by clinical data from the ALTITUDE and CLARIFY studies.

Analysis

Biodesix (NASDAQ:BDSX) presented a compelling growth narrative at the William Blair Growth Stock Conference on June 4, 2025, underscored by a 'strongly positive' sentiment signal. The company reported robust Q1 2024 financial results, including $18 million in revenue, marking a 21% year-over-year increase. This growth was propelled by an 18% rise in its core Lung Diagnostic Tests segment, which generated $16.3 million, and a substantial 61% year-over-year expansion in Development Services. Biodesix maintained industry-leading gross margins near 80%. Looking ahead, management revised its fiscal year revenue guidance upwards to $80-$85 million and reaffirmed its target to achieve adjusted EBITDA breakeven in Q4 2025. Key strategic initiatives underpinning this outlook include the expansion of its U.S. sales force to 95 representatives by the end of 2025, with a novel strategic focus on primary care physicians to broaden market reach. Furthermore, securing inclusion of its diagnostic tests in the anticipated 2025 update of the American College of Chest Physicians (ACCP) guidelines, supported by forthcoming clinical data from the pivotal ALTITUDE and CLARIFY studies, is a critical objective. Innovation remains a core focus, with advancements in expanding Veristrat test indications, developing new risk of recurrence/MRD (Minimal Residual Disease) tests, and venturing into digital diagnostics, which are expected to be detailed further at an R&D day in fall 2025. The development services arm also shows promise with a $10.9 million contracted research backlog. Biodesix anticipates 2025 to be a 'transformative year' driven by these commercial, clinical, and product development milestones.

Key Decisions for Investors

• Investors should monitor Biodesix's execution towards its Q4 2025 adjusted EBITDA breakeven target and its achievement of the revised $80-$85 million annual revenue guidance, as these are key indicators of its strategic plan's success.
• The anticipated inclusion in updated 2025 ACCP guidelines and the forthcoming clinical data from the ALTITUDE and CLARIFY studies represent significant potential catalysts; their outcomes warrant close observation for their impact on test adoption and market penetration.
• Evaluate the traction of the expanded U.S. sales force, particularly its new primary care physician engagement strategy, and progress in the product pipeline, including MRD tests and digital diagnostics, as crucial drivers for sustained long-term growth and market leadership.